Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free
immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the
safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore,
the primary purpose of the present Phase 3 clinical trial is to demonstrate the safety and
efficacy of allogeneic islet transplantation in improving glycemic control in Type 1
diabetic patients using the UIC protocol that was developed and proven effective during the
Phase 1/2 clinical trial.